Dare Bioscience Inc (DARE) Stock Price, Quote & News

Company Profile

Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual aro...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 926 7655

Website: darebioscience.com

Address:

3655 Nobel Drive, Suite 260, San Diego, United States

BuyAndHoldStocks Feb. 21 at 11:43 AM

$DARE Some investors may have questioned when the CEO would commit her own capital to the company. Her decision to purchase Regulation A units—particularly at a premium to the current share price—can be interpreted as a meaningful signal of confidence in the company’s valuation and forward prospects. Insider participation on these terms is typically viewed as a strong alignment of interests between management and shareholders. That said, insider transactions can be driven by a range of considerations and should be evaluated within the broader context of the company’s financial position, capital needs, and strategic trajectory. The ultimate impact of this purchase will depend on whether it is accompanied by tangible operational progress and supportive news flow. If so, it could help reinforce investor confidence and stimulate additional demand for the offering.

0 · Reply

BuyAndHoldStocks Feb. 21 at 9:01 AM

$DARE Dare Bioscience director and CEO Sabrina Martucci Johnson reported an acquisition of preferred stock and warrants tied to a Regulation A unit purchase. She subscribed on February 18, 2026 to purchase 10,800 Investor Units at $5 per Unit, with issuance to occur when the company accepts her subscription. https://ir.darebioscience.com/static-files/bc20299e-183d-42cf-9eb5-d61663e1d0d3

0 · Reply

BuyAndHoldStocks Feb. 20 at 4:57 PM

$DARE The fact that hedge fund Two Sigma bought Dare last quarter is a good sign. On February 17, 2026 - Two Sigma Investments, Lp filed a 13F-HR form disclosing ownership of 33,036 shares of Daré Bioscience, Inc. (US:DARE) valued at $63,759 USD as of December 31, 2025. On February 17, 2026 - Two Sigma Advisers, Lp filed a 13F-HR form disclosing ownership of 17,900 shares of Daré Bioscience, Inc. (US:DARE) valued at $34,547 USD as of December 31, 2025.

0 · Reply

BuyAndHoldStocks Feb. 19 at 7:52 PM

$DARE Going short at the current price level is not very wise. However, they have to continue to maintain the trend and hope that some of us retail will give up. I accumulate every week.

0 · Reply

BuyAndHoldStocks Feb. 19 at 5:25 PM

$DARE Institutional investors continue to accumulate. 1,217,174 - 8.52% (ex 13D/G) - change of 0.12MM shares 11.28%. Cautious accumulation. There have also been new investors in the last quarter.

0 · Reply

BuyAndHoldStocks Feb. 19 at 4:11 PM

$DARE Investor Positioning: Dare vs. Wisp – Scalable Women’s Health Platforms Actual results may differ materially due to market conditions, operational factors, regulatory developments, and other risks. Prospective investors are encouraged to conduct their own independent analysis and due diligence before making any investment decisions. 1. Comparable Commercial Models Dare’s evolving commercialization strategy can be compared to Wisp, a leading U.S. direct-to-consumer (D2C) telehealth platform specializing in women’s health (including a product with Sildenafil Cream, OMG! Cream for Female Arousal) and now majority-owned by WELL Health Technologies. Both models share key characteristics: • Digital-first patient acquisition • Telehealth-enabled prescribing • National U.S. reach • Recurring revenue potential • Asset-light infrastructure • High gross margin profile

1 · Reply

BuyAndHoldStocks Feb. 19 at 3:16 PM

$DARE Obviously the order flow is almost exclusively from short sellers. We'll see what their plan is when their cost increases.

0 · Reply

PriceRover Feb. 18 at 10:09 AM

$DARE Women’s health biotech with binary regulatory outcomes.

0 · Reply

CrossSectional Feb. 17 at 1:11 PM

$DARE Pre-revenue biotech; early-stage.

1 · Reply

sweepjosh Feb. 17 at 8:42 AM

$DARE Pre-revenue biotech; early-stage

0 · Reply

DARE to PLAY™ Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility

Nov 22, 2025, 7:23 AM EST - 3 months ago

Daré Bioscience, Inc. (DARE) Discusses DARE to PLAY Sildenafil Cream as a Treatment Option for Female Genital Arousal Concerns Transcript

Nov 13, 2025, 7:41 PM EST - 3 months ago

Daré Bioscience, Inc. (DARE) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 4:01 PM EST - 3 months ago

Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 6, 2025, 8:00 AM EST - 3 months ago

Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025

Sep 24, 2025, 8:00 AM EDT - 5 months ago

Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research

Aug 14, 2025, 7:48 PM EDT - 6 months ago

Daré Bioscience, Inc. (DARE) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 4:01 PM EDT - 6 months ago

Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 7, 2025, 8:00 AM EDT - 7 months ago

Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025

Jul 29, 2025, 8:00 AM EDT - 7 months ago

Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream

Jul 21, 2025, 1:47 PM EDT - 7 months ago

UPDATE - Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar

Jul 14, 2025, 1:09 PM EDT - 7 months ago

Crude Oil Moves Lower; Daré Bioscience Shares Jump

Jul 14, 2025, 8:00 AM EDT - 7 months ago

Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive

Jul 11, 2025, 8:00 AM EDT - 8 months ago

Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders

Jun 12, 2025, 5:00 PM EDT - 9 months ago

Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders

May 13, 2025, 11:13 PM EDT - 10 months ago

Daré Bioscience, Inc. (DARE) Q1 2025 Earnings Call Transcript

May 13, 2025, 4:01 PM EDT - 10 months ago

Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update

Mar 31, 2025, 10:14 PM EDT - 11 months ago

Daré Bioscience, Inc. (DARE) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 4:01 PM EDT - 11 months ago

Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update

Mar 24, 2025, 8:00 AM EDT - 11 months ago

Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025

Feb 6, 2025, 8:00 AM EST - 1 year ago

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development

Jan 9, 2025, 8:00 AM EST - 1 year ago

Daré Bioscience to Participate in the Women's Health Series at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 14, 2024, 8:03 PM EST - 1 year ago

Daré Bioscience, Inc. (DARE) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 4:01 PM EST - 1 year ago

Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update

Nov 7, 2024, 8:00 AM EST - 1 year ago

Daré Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024

Oct 23, 2024, 12:30 PM EDT - 1 year ago

Daré Bioscience Selected to Receive $10 Million Award from ARPA-H's Sprint for Women's Health

Oct 21, 2024, 8:05 AM EDT - 1 year ago

Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC

Aug 12, 2024, 8:40 PM EDT - 1 year ago

Daré Bioscience, Inc. (DARE) Q2 2024 Earnings Call Transcript

Aug 12, 2024, 4:01 PM EDT - 1 year ago

Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update

Jul 19, 2024, 8:00 AM EDT - 1 year ago

Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule

Jul 1, 2024, 6:54 AM EDT - 1 year ago

Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors

KPRX

Jun 27, 2024, 8:00 AM EDT - 1 year ago

Daré Bioscience Announces Reverse Stock Split

May 14, 2024, 6:30 PM EDT - 1 year ago

Daré Bioscience, Inc. (DARE) Q1 2024 Earnings Call Transcript

May 14, 2024, 8:00 AM EDT - 1 year ago

Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update

May 2, 2024, 8:00 AM EDT - 1 year ago

Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network

Apr 30, 2024, 7:30 AM EDT - 1 year ago

Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women's Health Product Candidates through Key Catalysts

Apr 23, 2024, 8:00 AM EDT - 1 year ago

Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

Apr 11, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive

Mar 28, 2024, 8:47 PM EDT - 2 years ago

Daré Bioscience, Inc. (DARE) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update

Mar 21, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024

Mar 15, 2024, 2:33 PM EDT - 2 years ago

This overlooked corner of women's health could be a $350 billion market opportunity

PFE PGNY VTGN BTMD

Jan 31, 2024, 8:00 AM EST - 2 years ago

Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024

Jan 26, 2024, 4:30 PM EST - 2 years ago

Daré Bioscience Announces Executive Team and Board of Directors Changes

Jan 17, 2024, 8:00 AM EST - 2 years ago

Daré Bioscience Announces Grant to Support Biotherapeutic Product Development

Jan 4, 2024, 8:00 AM EST - 2 years ago

Daré Bioscience's DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women's Health as well as in Treating a Broad Range of Diseases

Dec 26, 2023, 8:00 AM EST - 2 years ago

Daré Bioscience Secures $12 million in Royalty-backed Investment Structure

Dec 20, 2023, 8:00 AM EST - 2 years ago

Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study

Dec 13, 2023, 8:00 AM EST - 2 years ago

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical Study

Nov 9, 2023, 9:56 PM EST - 2 years ago

Daré Bioscience, Inc. (DARE) Q3 2023 Earnings Call Transcript

BuyAndHoldStocks Feb. 21 at 11:43 AM

0 · Reply

BuyAndHoldStocks Feb. 21 at 9:01 AM

0 · Reply

BuyAndHoldStocks Feb. 20 at 4:57 PM

0 · Reply

BuyAndHoldStocks Feb. 19 at 7:52 PM

$DARE Going short at the current price level is not very wise. However, they have to continue to maintain the trend and hope that some of us retail will give up. I accumulate every week.

0 · Reply

BuyAndHoldStocks Feb. 19 at 5:25 PM

$DARE Institutional investors continue to accumulate. 1,217,174 - 8.52% (ex 13D/G) - change of 0.12MM shares 11.28%. Cautious accumulation. There have also been new investors in the last quarter.

0 · Reply

BuyAndHoldStocks Feb. 19 at 4:11 PM

1 · Reply

BuyAndHoldStocks Feb. 19 at 3:16 PM

$DARE Obviously the order flow is almost exclusively from short sellers. We'll see what their plan is when their cost increases.

0 · Reply

PriceRover Feb. 18 at 10:09 AM

$DARE Women’s health biotech with binary regulatory outcomes.

0 · Reply

CrossSectional Feb. 17 at 1:11 PM

$DARE Pre-revenue biotech; early-stage.

1 · Reply

sweepjosh Feb. 17 at 8:42 AM

$DARE Pre-revenue biotech; early-stage

0 · Reply

Don_Frye Feb. 13 at 7:39 PM

$DARE zzzzzz

0 · Reply

zhusjason1 Feb. 13 at 4:42 PM

$DARE I think you are in a wrong place to practice your skills. Sounded like that this stock is very volatile 😅😅😅

0 · Reply

BuyAndHoldStocks Feb. 13 at 3:05 PM

$DARE Spread 1.71 to 1.77 • Highest buyer (bid): 1.71 • Lowest seller (ask): 1.77 • Difference: 0.06 • Spread ≈ 3.5% Interesting squeeze signal: • The spread was previously days normal • It suddenly widens • Volume surges (3–5x normal) • Pullbacks are bought immediately → Short sellers may be under pressure

1 · Reply

BuyAndHoldStocks Feb. 12 at 6:36 PM

$DARE ”we’ve solved the hard problems, we have a platform that is ready to now engage with.” ”So to facilitate future partnerships, we’ve invested in custom manufacturing capabilities – cleanrooms, manufacturing space – so that we’re ready to start making products across multiple potential applications.” Value 💰🔥

0 · Reply

BuyAndHoldStocks Feb. 12 at 6:25 PM

$DARE Daré Bioscience’s DARE‑LARC1 product is built on an extensive portfolio of microchip delivery patents from Microchips Biotech and MIT researchers, including notable patents such as: • US 5,797,898 A – Microchip drug delivery devices • US 6,123,861 A – Fabrication of microchip drug delivery devices • US 7,892,221 B2 – Reservoir-based implants for controlled drug release • US 8,277,440 B2 – Implants for controlled, extended drug delivery • US 10,427,153 B2 – Later technological improvements

1 · Reply

BuyAndHoldStocks Feb. 12 at 3:35 PM

$DARE Contraceptive Efficacy Study of Ovaprene Latest Update: December 2025 Between September and December, five additional study sites were completed. In addition, three sites changed their status to “Active, not recruiting.” At the midpoint (115 patients) of the study, a total of seven sites had been completed. Assuming that patient enrollment is relatively evenly distributed across study centers, it is reasonable to estimate that approximately 250 patients could complete the study during 2026. The overall study completion date remains unchanged at September 2026 (estimated). https://clinicaltrials.gov/study/NCT06127199?tab=history&a=13&b=15#version-content-panel

0 · Reply

BuyAndHoldStocks Feb. 12 at 3:13 PM

$DARE DARE to RESTORE™ consists of non-prescription vaginal probiotics. Target Launch Timing: The products are targeted for availability in the first quarter of 2026.

0 · Reply

BuyAndHoldStocks Feb. 12 at 12:06 PM

$DARE The On-Balance Volume (OBV) indicator typically moves in tandem with a stock’s price, reflecting the balance between buying and selling pressure. However, in Dare’s case, OBV has not declined to the same extent as the share price. This divergence suggests that the recent price weakness has not been accompanied by a comparable increase in selling volume. However, volume spikes have made it more difficult to interpret OBV and draw conclusions about buy signals. Larger investors buy volume over time when there is volume in the market and that is what will lift the stock quickly when the right news comes.

1 · Reply

BuyAndHoldStocks Feb. 12 at 11:53 AM

$DARE A short hedge fund is trying to make it look like there’s no bottom, targeting weak-handed investors. Short Volume Ratio was 64,15% yesterday. Last Wednesday 65.85% then at significantly higher volume. Their goal is to shake out sellers so they can buy back cheaper. Meanwhile, patient buyers are waiting for more news before stepping in, creating a temporary imbalance that doesn’t reflect the stock’s true value.

1 · Reply

BuyAndHoldStocks Feb. 12 at 10:03 AM

$DARE Read https://www.ainvest.com/news/dar-play-assessing-scalability-market-capture-potential-kind-topical-arousal-treatment-2602/

0 · Reply

GolfPro999 Feb. 11 at 1:14 PM

$DARE

0 · Reply

BuyAndHoldStocks Feb. 11 at 10:39 AM

$DARE We'll see tomorrow if the combination of testing through Evvy and treatment with XACIATO yielded sales results for Organon. They have also invested a lot in marketing lately. https://www.organon.com/news/organon-and-evvy-announce-collaboration-to-expand-access-of-xaciato-clindamycin-phosphate-vaginal-gel-2-a-treatment-for-bacterial-vaginosis/

1 · Reply

Market Cap	23.86M
Revenue (ttm)	10,000.00
Net Income (ttm)	-4.05M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	1.34
Profit Margin	-40,500.00%
Debt to Equity Ratio	0.00

Volume	31,600
Avg Vol	166,384
Day's Range	N/A - N/A
Shares Out	14.29M
Stochastic %K	8%
Beta	0.93
Analysts	Strong Sell
Price Target	$10.75